li001

Researchers are reporting a major advance in multiple myeloma treatment with a new class of drugs called CELMoDs (cereblon E3 ligase modulators), including iberdomide and mezigdomide. These drugs are stronger than traditional IMiDs like Revlimid, killing cancer cells directly while also boosting the immune system by activating T-cells and Natural Killer cells. They also tend

New research highlights a growing shift toward more personalized and less aggressive treatment for Prostate Cancer, with a strong focus on improving patients’ quality of life. Doctors are moving away from a one-size-fits-all approach and using new data to identify which patients truly need intensive therapy and which may safely avoid certain treatments. Results from

New research suggests that combining the experimental drug evorpacept with the HER2-targeted therapy zanidatamab may help patients with heavily treated HER2-positive metastatic breast cancer. Evorpacept works by blocking CD47, a signal cancer cells use to avoid being destroyed by the immune system. Researchers also found that patients whose tumors had higher CD47 levels responded better

Treatment for HER2-positive metastatic breast cancer is evolving as antibody-drug conjugates (ADCs) move earlier in therapy. The long-standing first-line standard has been a taxane chemotherapy combined with trastuzumab and pertuzumab (THP), established by the CLEOPATRA trial. However, the DESTINY-Breast09 trial reported that trastuzumab deruxtecan (T-DXd) plus pertuzumab significantly improved outcomes, with progression-free survival reaching 40.7